vimarsana.com

Latest Breaking News On - Genitourinary malignancies branch - Page 1 : vimarsana.com

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.

United statesSan franciscoToni choueiriDorothy byrnePaulv viscuseRobert motzerNancy kohlbergHarvard medical schoolGenitourinary tumors multidisciplinary clinic centerMemorial sloan kettering cancer centerInternational metastatic renal cell carcinoma database consortiumLank centerCancer research of the national instituteGenitourinary oncology serviceGenitourinary oncology at dana farber cancer instituteUniversity of virginia

Pembrolizumab Improves Disease-Free Survival for Muscle-Invasive Urothelial Carcinoma

The late-breaking data at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium included the results of KEYNOTE-123 for locally advanced resectable urothelial carcinoma.

United statesNational cancer instituteMerck research laboratoriesNational institutes of healthClinical oncology genitourinary cancersAfter surgeryLocalized muscle invasive bladder cancerLocally advanced urothelialNational cancerCompletion dateBladder cancer sectionGenitourinary malignancies branchNational institutes

AMBASSADOR: Adjuvant Pembro Boosts DFS in Urothelial Cancer

Interim findings from the ongoing AMBASSADOR trial revealed a significant DFS benefit with adjuvant pembrolizumab but no overall survival benefit at this point.

United statesJohns hopkins universityMax katesGenitourinary malignancies branchNational cancer instituteDrug administrationBladder cancer program at johns hopkins universityCancer researchClinical oncology genitourinary cancerBladder cancer sectionBacillus calmette guBladder cancer programBladder cancerAlignant bladder neoplasmUrothelial cancerAlignant neoplasia

Dr Apolo on Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma

Andrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma.

National institutes of healthGenitourinary malignancies branchBladder cancer sectionBladder cancerGenitourinary tumors multidisciplinary clinicNational institutesAndreab apoloAmbassador alliance a031501 trialAdjuvant pembrolizumabLocally advanced muscle invasive urothelial carcinoma

Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer

Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option.

United statesCancer research of the national instituteAmerican society of clinical oncologyDevelopment agreementNational cancer instituteNational institutes of healthAlliance for clinical trials in oncologyClinical trialsClinical oncologyCancers symposiumBladder cancer sectionGenitourinary malignancies branchBladder cancerGenitourinary tumors multidisciplinary clinicCancer researchNational cancer

vimarsana © 2020. All Rights Reserved.